- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Fluorescein Sodium.
Displaying page 1 of 2.
EudraCT Number: 2011-002527-18 | Sponsor Protocol Number: FluoGlio2011 | Start Date*: 2011-07-06 |
Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | ||
Full Title: Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas. | ||
Medical condition: Intracranial high grade gliomas | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004512-58 | Sponsor Protocol Number: INV-GEM-0200-I | Start Date*: 2020-08-17 | |||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin | |||||||||||||
Full Title: Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation | |||||||||||||
Medical condition: Intracranial tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004929-33 | Sponsor Protocol Number: SiccaIkervis | Start Date*: 2018-12-05 |
Sponsor Name:KH Hietzing, Department of Ophthalmology | ||
Full Title: Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome | ||
Medical condition: primary or secondary Sjögren Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004127-79 | Sponsor Protocol Number: STALMANSHUA | Start Date*: 2018-05-09 |
Sponsor Name:UZ Leuven | ||
Full Title: Comparison of treatment with preservative-free versus preserved dexamethasone 0.1% and diclofenac 0.1% eye drops after cataract surgery. | ||
Medical condition: Treatment after cataract surgery | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002158-15 | Sponsor Protocol Number: SYL1001_V | Start Date*: 2022-11-17 | |||||||||||
Sponsor Name:Sylentis SAU | |||||||||||||
Full Title: Tivanisiran for Dry Eye in Subjects with Sjögren’s Syndrome | |||||||||||||
Medical condition: Dry Eye Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002163-26 | Sponsor Protocol Number: PRI2017HUS7040 | Start Date*: 2018-07-03 | |||||||||||
Sponsor Name:Hôpitaux Universitaires de Strasbourg | |||||||||||||
Full Title: Pilot study on doxorubicin kinetic distribution during arterial chemoembolization | |||||||||||||
Medical condition: hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009998-10 | Sponsor Protocol Number: MYCUV-IIT02 | Start Date*: 2010-02-24 | |||||||||||
Sponsor Name:Centre for Ophthalmology, University of Tuebingen | |||||||||||||
Full Title: Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial | |||||||||||||
Medical condition: non-infectious uveitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002238-35 | Sponsor Protocol Number: 11002X-001 | Start Date*: 2012-10-04 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye Drop Formulation with OPTIVE™ Unit-Dose for 3 Months in Subjects with Dry Eye Disease | |||||||||||||
Medical condition: Dry Eye Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004106-25 | Sponsor Protocol Number: EOP 1011E | Start Date*: 2005-03-31 | |||||||||||
Sponsor Name:(OSI) Eyetech, Inc | |||||||||||||
Full Title: A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium c... | |||||||||||||
Medical condition: Exudative Age Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003547-36 | Sponsor Protocol Number: NRL972-09/2008- (CHBC) | Start Date*: 2009-02-12 | |||||||||||
Sponsor Name:Norgine Ltd | |||||||||||||
Full Title: An open study to investigate the effects of chronic hepatitis B or C on the pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) before, during and after standard treatment | |||||||||||||
Medical condition: In-vivo diagnostic marker for liver dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003147-27 | Sponsor Protocol Number: B1261009 | Start Date*: 2014-01-10 | ||||||||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY 10017 US | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF ... | ||||||||||||||||||
Medical condition: PF-04634817 is a small molecule chemokine CCR2/5 receptor antagonist that is being developed for the treatment of diabetic nephropathy and diabetic macular edema. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000214-34 | Sponsor Protocol Number: SYL1801_II | Start Date*: 2022-10-08 | |||||||||||
Sponsor Name:SYLENTIS S.A.U | |||||||||||||
Full Title: A Randomized, Double masked, Parallel group, Dose-finding study to evaluate SYL1801 in patients with neovascular AMD | |||||||||||||
Medical condition: Wet form of Neovascular Age-Related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) CZ (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003018-42 | Sponsor Protocol Number: OPH1004 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination wi... | ||||||||||||||||||
Medical condition: Subfoveal neovascular age-related macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Prematurely Ended) ES (Prematurely Ended) FI (Completed) NO (Completed) DE (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) IT (Completed) AT (Prematurely Ended) HU (Completed) HR (Prematurely Ended) CZ (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000518-23 | Sponsor Protocol Number: OPH1007 | Start Date*: 2015-10-20 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination w... | ||||||||||||||||||
Medical condition: Subfoveal neovascular age-related macular degeneration (AMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) HR (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001460-32 | Sponsor Protocol Number: EOP1013B | Start Date*: 2006-02-15 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A phase 2/3 randomized, controlled, double-masked, multicenter, comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium ... | |||||||||||||
Medical condition: diabetic macular edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) AT (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) BE (Completed) DE (Completed) GR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001708-19 | Sponsor Protocol Number: SVS20-EUR-06-01 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:TRB CHEMEDICA INTERNATIONAL SA | |||||||||||||
Full Title: A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, ... | |||||||||||||
Medical condition: treatment on bilateral moderate dry eye syndrome due to Sjögren's syndrome or diagnosed as a primary syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000519-42 | Sponsor Protocol Number: OPH1008 | Start Date*: 2015-10-26 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therap... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004663-22 | Sponsor Protocol Number: NRL972-05/2007 (ETOH) | Start Date*: 2008-04-14 | |||||||||||
Sponsor Name:Norgine Limited | |||||||||||||
Full Title: A multi-centre, open short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting. | |||||||||||||
Medical condition: Alcoholic liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002930-19 | Sponsor Protocol Number: XBR1001 | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Xbrane Biopharma | |||||||||||||
Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
Medical condition: Wet Age-related macular degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003391-35 | Sponsor Protocol Number: LT1910-PIV-01/06 (NL) | Start Date*: 2006-09-13 | |||||||||||
Sponsor Name:Laboratoires THEA | |||||||||||||
Full Title: Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögre... | |||||||||||||
Medical condition: keratoconjunctivitis sicca | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.